ESMO and IASLC are pleased to invite journalists to a media brief taking place at the beginning of the European Lung Cancer Conference (ELCC) in the Palexpo Centre in Geneva, on Friday 5 May 2017, from 12:00 to 12:45 CEST.
The Scientific Co-Chairs of ELCC 2017, Professors Martin Reck (ESMO) and Andrew Nicholson (IASLC) will be present to answer media questions, as well as Professor Solange Peters from the ELCC Scientific Committee.
Some of the news that will be released about ELCC 2017 includes:
- Men need more frequent lung cancer screening than women
- White blood cell counts can predict whether lung cancer patients will benefit from immunotherapy
- Osimertinib improves symptoms in advanced lung cancer patients
- Annual flu jab may pose greater risk for cancer patients on checkpoint inhibitors
- Some lung cancer patients benefit from immunotherapy even after disease progression
- Patients with NSCLC respond best to salvage chemotherapy when pre-treated with PD-1/PD-L1 inhibitors
Three late breaking studies will be announced at ELCC 2017:
- LBA1: Establishment of a diagnostic algorithm for ROS1 testing in Canada
- LBA2_PR: Use of G-CSF and prophylactic antibiotics with concurrent chemo-radiotherapy in limited-stage small cell lung cancer: results from the phase III CONVERT trial
- LBA3: Correlation between clinical outcomes of patients treated within the TAILOR trial and Next-Generation Sequencing (NGS) results: analysis of genes associated to KRAS mutations
Martin Reck, Germany, said: “Some of the most exciting developments in lung cancer will be discussed at ELCC. One of the foremost today is immunotherapy. I look forward to the abstract sessions, where important new data about the activity of anti-PDL1 antibodies in first-line treatment and in patients with squamous cell NSCLC will be presented. I also look forward to the updated educational program, which will provide a comprehensive overview of the development of the emergent field of immunotherapy in thoracic tumours."
Andrew Nicholson, UK, said: “It is difficult to choose one area when there is so much progress in diagnosis, prognosis and advances in targeted therapy and immunotherapy, but I am excited about the presentation on the setting up of ROS1 testing in Canada, because it presents issues on how testing for rare abnormalities can be nationally implemented.”
Lung cancer killed approximately 1,590,000 persons in 2012 and is currently the leading cause of cancer death worldwide (1). Tobacco use is a major risk factor for lung cancer and is responsible for approximately 22% of cancer-related deaths globally. Lung cancer is the leading cause of cancer deaths in males and the second leading cause in females globally. In 2012, lung cancer killed an estimated 1,098,700 men and 491,200 women worldwide, corresponding to 24% and 14% of all cancer deaths in males and females, respectively (1). In developed countries, it is now the leading cause of cancer death in females, surpassing breast cancer (2).
The European Lung Cancer Conference is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.
Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card.
Media representatives are required to observe and abide by the ELCC Media Policy
To register for the event, please fill out the Complimentary Media Registration Form.
- Abstracts accepted for presentation and for publication in the ELCC 2017 Abstract Book will be published online on the ELCC 2017 section of the ESMO website on Wednesday, 26 April 2017 12:00 (CEST).
- Late Breaking Abstracts will be released at the beginning of session where they are presented
- Abstracts selected for the official ELCC 2017 Press Programme (suffix _PR) will be made public starting on 26 April and at the latest at the start of the scientific session where they are being presented
Journalists are required to observe embargoes as indicated, thank you!
We look forward to welcoming you in Geneva or to help you with any inquiry about remote coverage of ELCC 2017.
The ELCC Press Office Team
30 Route François-Peyrot
1218 Le Grand-Saconnex
- WHO IARC. GLOBOCAN 2012: Estimated Cancer Incidence Mortality and Prevalence Worldwide in 2012. Lung cancer statistics
- American Cancer Society: Global Cancer Facts & Figures, 3rd Edition
About the European Lung Cancer Conference (ELCC) 2017
The European Lung Cancer Conference (ELCC) is the reference event in Europe for professionals treating lung cancers. It is organised by the European Society for Medical Oncology and the International Association for the Study of Lung Cancer in partnership with ESTRO and ETOP.
ELCC provides a comprehensive multidisciplinary overview of the latest as well as of the state-of-the-art knowledge in thoracic malignancies, covering different aspects such as prevention, screening, diagnosis, treatment modalities and the results of basic, clinical and translational research, presented by top international academic experts. Around 2,000 attendees are expected from throughout Europe and the rest of the world.
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With more than 15,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.
About the International Association for the Study of Lung Cancer (IASLC)
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes more than 5,000 lung cancer specialists in over 100 countries. Visit www.iaslc.org for more information.